Pharmacort

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pharmacort

What is Pharmacort?

Pharmacort is a potent prescription medication containing the active ingredient Hydrocortisone (as sodium succinate). It is classified as a glucocorticoid, belonging to the larger pharmacological class of corticosteroids.

This specific formulation is most commonly prepared as a lyophilized powder for injection (I.M. or I.V. administration). This design allows for rapid dissolution and immediate intravenous delivery, which is essential for managing acute medical emergencies.

Property Description
Active ingredient Hydrocortisone (as sodium succinate)
Form Powder for Injection
Pharmacological class Corticosteroid / Glucocorticoid
Common use Treatment of severe inflammation and immune disorders
Origin Prescription Drug (Rx)

Medical Use and Credibility

Hydrocortisone is a synthetic version of cortisol, a naturally occurring hormone produced by the adrenal glands. It is used for its anti-inflammatory and immunosuppressive properties in a variety of disorders. The drug works by suppressing inflammation and modifying the body's immune response.

Hydrocortisone is a corticosteroid medication utilized for reducing swelling and redness by changing how the immune system functions.

This drug class is used for its broad therapeutic applications in treating conditions across many organ systems where the immediate control of inflammation is necessary. The highly soluble succinate salt used in Pharmacort is designed to achieve quick, high blood levels, making it a tool in acute care settings.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Pharmacort?

Possible side effects and safety information

The safety profile of Pharmacort (Hydrocortisone Sodium Succinate) is based on its classification as a systemic glucocorticoid, as documented in official government regulatory sources such as the FDA and EMA. Potential adverse reactions are grouped by System-Organ Class (SOC) and are typically dose- and duration-dependent.


Adverse Reaction Categories and Classification

The official documentation lists effects across several physiological systems. Common regulatory categories include Metabolism and Nutrition Disorders (e.g., fluid retention, hyperglycemia), Musculoskeletal Disorders (e.g., osteoporosis, muscle weakness), Endocrine Disorders (e.g., HPA axis suppression, Cushingoid state), and Infections and Infestations (decreased resistance to infection).

Reactions associated with high-dose, short-term use, such as peptic ulceration, are generally classified as uncommon. Other psychiatric and neurological disturbances, including mood swings, insomnia, and headache, are also documented.


Serious Adverse Reactions and Restrictions

Serious Adverse Reactions officially listed include acute drug hypersensitivity, such as anaphylactic/anaphylactoid reactions, and severe gastrointestinal complications, including ulcer perforation and hemorrhage.

The drug is contraindicated in individuals with systemic fungal infections or known hypersensitivity to the active ingredient. Additionally, regulatory safety information explicitly restricts its use, stating it must not be administered intrathecally or epidurally due to reports of severe neurological events.


Population and Exposure Considerations

Safety notes for specific populations exist in the official labeling: pediatric patients are monitored for potential suppression of growth, and caution is advised for older adults who may have an increased risk of conditions like osteoporosis. Risks such as adrenocortical insufficiency and steroid withdrawal syndrome are officially linked to the discontinuation of prolonged therapy, highlighting the importance of the duration-related safety pattern.

Overdose and Emergency Response

Overdose and When to Seek Help

Documented Overdose Profile

Overdose with Pharmacort is typically categorized based on the exposure duration. Acute overdose may primarily manifest as disturbances in body fluids and electrolytes. In contrast, prolonged chronic overuse or administration of supra-physiological doses is officially documented to lead to symptoms consistent with Cushing's syndrome (Hyperadrenocorticism).

Severe acute consequences documented in official regulatory labeling may include seizures (convulsions), profound heart rhythm disturbances, and the potential for life-threatening acute adrenal insufficiency (adrenal crisis), especially upon abrupt withdrawal after chronic high-dose exposure.

When to Seek Emergency Medical Attention

Immediate medical help must be sought for any suspected or actual overdose. Official emergency-response statements instruct individuals to call an emergency number (e.g., 911 or equivalent) or a Poison Control Center right away for guidance.

Treatment described in regulatory sources focuses on supportive care to manage symptoms and maintain vital functions, which involves continuous monitoring of the patient's cardiovascular and respiratory status and managing any severe fluid or electrolyte changes. Individuals experiencing signs of severe symptoms, such as seizures or profound heart rhythm changes, require immediate transport to an Emergency Room.

Therapeutic Uses of Pharmacort

What Pharmacort Treats: Main Uses and Benefits

Pharmacort is commonly used across conditions presenting with acute episodes and symptoms related to inflammatory or irritative states. The medication is considered relevant in contexts involving a heightened systemic burden, and may assist with easing symptoms related to inflammatory or irritative states. It helps address symptom clusters that may become intense or disruptive, such as noticeable pain, redness, and swelling in joints or tissues. This therapeutic approach is used across conditions including certain autoimmune disorders, severe allergies, inflammatory bowel disease, and is relevant for managing symptoms related to hormonal deficiency. These applications provide support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.

The medicine is also relevant when supportive symptom management is appropriate for symptoms related to heightened physiological activity (such as immune overactivity and allergies). Applied across domains where additional symptomatic support is needed, it assists in managing challenging allergic or autoimmune manifestations. Furthermore, it is applied in scenarios where additional management of discomfort is required due to symptoms related to systemic imbalance, such as hormonal deficiency symptoms.

“It helps address symptom clusters that may become intense or disruptive.”

Quick Fact: Relief for Inflammatory and Systemic Symptoms

Regulatory References

  1. NIH MedlinePlus overview on Prednisone

Eligibility and Restrictions for Use

The official regulatory profile for Pharmacort (Hydrocortisone Sodium Succinate Injection) establishes clear eligibility and non-eligibility rules based on patient population, pre-existing conditions, and administration route.

Populations for Whom Use is Contraindicated

The medicine is contraindicated and must not be used in patients with systemic fungal infections or a known hypersensitivity to the active substance or its constituents. Administration via the intrathecal or epidural routes is also contraindicated due to associated reports of severe medical events. Furthermore, the intramuscular route is contraindicated for patients with Idiopathic Thrombocytopenic Purpura (ITP).

Age-Related and Condition-Specific Eligibility

Use is established in adults and children older than one month of age. Safety and efficacy have not been established in children one month of age and younger. Particular care is required and close monitoring is necessary for patients with certain pre-existing conditions, including severe liver or renal impairment, hypertension, congestive heart failure, peptic ulceration, or latent tuberculosis. The parenteral formulation is classified as US FDA Category C for pregnancy, meaning use is restricted unless the potential benefit outweighs the risk to the fetus.

What should I know about interactions with other medicines?

The interaction profile for Pharmacort (Hydrocortisone) is defined by specific pharmacokinetic and pharmacodynamic interaction patterns documented in official government regulatory labels.

Metabolic Clearance and Exposure

Hydrocortisone's clearance is primarily dependent on the CYP3A4 enzyme system. Co-administration with strong CYP3A4 Inhibitors, such as Ketoconazole or Ritonavir, is documented to significantly increase Hydrocortisone plasma concentrations by reducing its metabolic clearance. Conversely, strong CYP3A4 Inducers, including Phenytoin and Rifampin, may decrease systemic exposure due to accelerated metabolic clearance, potentially reducing its effect. Additionally, the use of Oral Contraceptives containing estrogens is noted to increase Hydrocortisone's systemic exposure by reducing its clearance.


Pharmacodynamic and Restriction-Based Interactions

Certain co-administered medicinal products lead to officially described additive or antagonistic effects. Concurrent use with Potassium-Depleting Agents, such as certain diuretics, enhances the documented risk of hypokalemia (low potassium levels). Use alongside Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is documented to increase the risk of gastrointestinal adverse effects, such as ulceration. Official regulatory documents classify the co-administration of Live or Live Attenuated Vaccines as contraindicated when Pharmacort is administered at immunosuppressive doses, owing to the potential for severe infection. This restriction is also noted for combinations with Mifepristone.

Mechanism of Action

Targeting the Glucocorticoid Receptor to Modulate Gene Expression

Pharmacort works by acting as an agonist for the Glucocorticoid Receptor (GR), a protein found inside nearly all body cells. Following cell entry, the drug-receptor complex moves into the nucleus, where it alters the cell's genetic output, initiating all downstream physiological effects.

The Mechanistic Cascade: Suppressing Inflammation and Immunity

The activated receptor complex primarily shuts down (transrepresses) the master regulators of inflammation, such as NF-κB, limiting the cell's production of pro-inflammatory messengers like cytokines and chemokines. This molecular cascade results in a systemic anti-inflammatory and immunosuppressive physiological effect.

Systemic Effects: Modulating Metabolism and the HPA Axis

Pharmacort also induces (transactivates) genes involved in carbohydrate and fat metabolism, leading to physiological changes like elevated blood glucose and altered lipid profiles. Furthermore, the drug suppresses the Hypothalamic-Pituitary-Adrenal (HPA) axis via a negative feedback loop, which contributes to the drug's overall hormonal and metabolic consequences.

Dosage and Administration Information

How Pharmacort is Used: Official Administration and Dosing

Pharmacort (Hydrocortisone as sodium succinate) is a prescription medicine delivered by injection, strictly governed by official prescribing information to ensure its rapid and appropriate use in acute settings. The medicine is primarily intended for short-term, supervised administration.

Approved Administration and Preparation

Pharmacort is approved for parenteral administration via injection. For initial acute or emergency use, Intravenous (IV) injection is preferred due to the need for rapid effect, though Intravenous (IV) infusion and Intramuscular (IM) injection are also approved routes.

As a lyophilized powder, Pharmacort must be reconstituted with a sterile diluent (such as Sterile Water for Injections) prior to administration. For infusion, the reconstituted solution must be further diluted into a compatible large volume parenteral solution.

Standard Dosage and Use Parameters

Dosing is highly individualized based on the patient's condition. The following are the standard ranges and usage protocols outlined in clinical guidelines:

Parameter Official Instructions (Adults)
Initial Dose Range 100 mg to 500 mg or more, based on severity.
Repeat Frequency May be repeated every 2, 4, or 6 hours as required.
IV Injection Rate Administer large doses (500 mg) over 10 minutes; smaller doses (100 mg) over at least 30 seconds.
Acute Duration Limit High-dose therapy generally not continued beyond 48 to 72 hours.

Use Over Time and Special Considerations

After the initial acute period, the dosage should be gradually decreased at appropriate intervals to the lowest effective level. If treatment continues, the medicine must be withdrawn gradually (tapered) rather than abruptly. For pediatric patients, the dose is determined by the severity of the condition, not solely by age or weight, with a minimum dose of 25 mg daily.

Pharmacort should not be diluted or mixed with other solutions unless specified due to potential incompatibilities.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pharmacort


Evidence for Use in Adrenocortical Insufficiency (Primary or Secondary)

Pharmacort was evaluated in research contexts involving a need for hormone replacement due to systemic or functional imbalance. Since this is a critical replacement therapy, large-scale, placebo-controlled trials are typically not conducted. Instead, research structures include long-term observational studies, patient registries, and retrospective analyses that monitor patient health over extended time intervals.

These studies monitored outcomes related to systemic or functional imbalance, such as maintaining hormone levels and tracking the incidence of adrenal crises. Findings describe patterns observed in these studies, including how these key measurements evolved in the observed adult and pediatric populations over years of follow-up. The specifics of dosing required for achieving long-term systemic balance are not fully established by controlled research.


Evidence for Use in Rheumatoid Arthritis

Research explored short-term symptom changes in adults with active Rheumatoid Arthritis (RA), a condition characterized by fluctuating or episodic manifestations. These studies primarily involved short-term Randomized Controlled Trials (RCTs) against inactive substances or other active agents. These trials measured outcomes linked to inflammatory or irritative states and outcomes reflecting daily functioning or activity level.

Findings from these short-term trials reported how symptoms evolved in the observed populations, describing patterns related to changes in joint swelling and tenderness counts over defined time intervals. Follow-up durations were limited in most controlled studies, and there is limited information for the long-term consequence of short-term use on overall disease trajectory.


What is Still Uncertain About Pharmacort Research

The evidence landscape currently highlights several areas where certainty remains low or data are still emerging. A key uncertainty is the lack of long-term, controlled data for many of Pharmacort's uses, particularly its intermittent application for acute flares, where follow-up durations were limited. Sample sizes were modest in some studies, meaning results apply only to the populations studied. Furthermore, evidence quality varies across studies, and comparative evidence is lacking, particularly regarding the specific outcomes of Pharmacort versus other systemic agents.

Key Studies & References

  1. Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs) (Case-crossover study)

Frequently Asked Questions (FAQ)

Common questions about Pharmacort (FAQ)


Q: How quickly does Pharmacort start working?

Official information states that because Pharmacort is given by injection (parenteral administration), high blood levels of the active ingredient are attained rapidly. Following intravenous injection, demonstrable physiological effects are typically evident within one hour.


Q: How long do the effects of Pharmacort last?

Regulatory information indicates that the effects of the dose persist for a variable period of time. The administered dose is mostly excreted from the body within 12 hours. If constantly high blood levels must be maintained, the injection may be repeated every few hours, as described in official prescribing information.


Q: Is it common to feel tired when taking Pharmacort?

Yes, official safety documentation lists side effects such as fatigue and tiredness or drowsiness. This may affect a patient's ability to perform tasks that require full attention.


Q: Is Pharmacort safe to use if I have kidney problems?

Official sources advise that this medicine should be administered cautiously in patients who have pre-existing kidney problems or renal dysfunction. Close monitoring is typically associated with the treatment of patients who have these pre-existing conditions.


Q: What should I do if I forget to take my regular dose of Pharmacort?

Since this medicine is usually given by a healthcare provider in a supervised setting, there is typically a strict dosing schedule. If a dose is believed to be missed, official patient information describes the need to consult a healthcare provider or pharmacist to determine the next steps and to avoid taking extra doses.


Q: Are there any foods or drinks I need to avoid while on Pharmacort?

Regulatory patient information states that grapefruit juice should be avoided. Official documents may also describe the need for certain dietary adjustments, such as a low-salt or high-potassium diet, during treatment.


Q: Does Pharmacort cause weight gain?

Yes, regulatory documentation lists weight gain as a documented side effect. This is often caused by the medicine's effect on fluid retention and altered metabolic processes.


Q: Can I take Pharmacort if I'm pregnant or trying to conceive?

Official information states that during pregnancy, the medication should be used only when clearly needed and only if the potential benefit justifies the risk. Infants born to mothers who have used the medicine long-term or at high doses may need to be observed for potential hormone problems.


Q: Is Pharmacort safe for older adults (seniors)?

Caution is advised when using this medicine in older adults because they may be more sensitive to certain side effects. Regulatory notes specifically mention the increased risk of developing conditions like osteoporosis (weak bones) in this population.


Q: Does Pharmacort have a risk of addiction or dependence?

Official safety documents emphasize the importance of tapering the dose after prolonged use to prevent steroid withdrawal syndrome. This describes a form of physical dependence that necessitates the gradual withdrawal of the medicine under supervision.


Q: Is Pharmacort considered a 'controlled' substance?

According to official regulatory classifications, the active ingredient, hydrocortisone sodium succinate, is Not a controlled drug (N/A CSA Schedule).


Q: Can I take ibuprofen or acetaminophen while using Pharmacort?

Official documentation states that co-administration with NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) such as ibuprofen may increase the risk of gastrointestinal adverse effects such as ulceration. Reviewing all medications with a healthcare professional helps ensure proper management of potential interactions.


Q: Are the side effects of Pharmacort permanent?

Most side effects are temporary and dose-dependent. However, official safety notes indicate that certain serious side effects, such as drug-induced adrenocortical insufficiency (low natural steroid levels), may persist for months after the medication is stopped. Other long-term effects like bone loss may also be long-lasting.


Q: Is it safe to drive or operate machinery after taking Pharmacort?

Official patient information advises patients to be cautious, as the medication may cause side effects like dizziness, lightheadedness, or visual disturbances. It is important that individuals understand how the drug affects them before performing these activities.


Q: What happens if I drink alcohol while taking Pharmacort?

Official safety information states that alcoholic beverages should be limited. Daily use of alcohol while taking this medicine may increase the risk for stomach bleeding. It can also potentially worsen side effects like dizziness.


Q: What is the half-life of Pharmacort?

While the exact pharmacological half-life is complex, official clinical pharmacology reports indicate that the administered dose is almost entirely excreted within 12 hours. This short duration of action is one reason why, in cases where continuously high blood levels are needed, the injection may be repeated every four to six hours.


Q: Is Pharmacort effective for pain relief?

Pharmacort is indicated for its anti-inflammatory and immunosuppressive effects. By reducing inflammation in conditions such as rheumatoid arthritis, the medicine may relieve related pain and swelling, but it is not formally indicated as a primary pain reliever.


Q: What is the recommended age range for using Pharmacort?

Official regulatory documents state that use of this medicine is established in children older than one month of age. Safety and effectiveness have not been established in children who are one month of age and younger.


Q: What is the research evidence for Pharmacort’s use in children?

Official research structures have included monitoring of pediatric patients using the drug for conditions like adrenocortical insufficiency. It is also officially noted that children on prolonged therapy are monitored for potential suppression of growth.


Q: Is Pharmacort safe for people with liver disease?

Caution is advised in patients with pre-existing conditions, including cirrhosis (a form of liver disease) and severe liver impairment. The presence of these conditions may impact how the body processes the medication, indicating a need for caution.


Q: Can men and women use Pharmacort for the same purposes?

Yes, the primary uses of the drug, which relate to its anti-inflammatory and immunosuppressive properties, apply to the general patient population. Official regulatory documents list no gender-specific restrictions for the main indications.


Q: Does Pharmacort have any known black box warnings?

While the official label for the approved injection product does not contain a traditional Black Box Warning, the FDA has issued a safety communication. It explicitly contraindicates the use of this drug by the intrathecal or epidural routes due to reports of severe, sometimes fatal, neurological events.

How should Pharmacort be stored and disposed of?

The storage and disposal of Pharmacort (hydrocortisone sodium succinate sterile powder for injection) must align precisely with official government regulatory instructions.

Storage Condition Official Requirement
Temperature (Unreconstituted) Controlled Room Temperature: 20 C to 25 C (68 F to 77 F)
Environmental Protection Must be protected from light and protected from freezing [Source 1.6, 2.1].
Stability (Post-Mixing) Use the solution within 12 hours (at room temperature) or 24 hours (if refrigerated), following preparation, and discard any unused portion [Source 2.1].
Child Safety Keep all medication out of the sight and reach of children [Source 1.1].

Official disposal requires following specific instructions on the labeling or utilizing a drug take-back program. If no program is available, unused medication may be mixed with an undesirable substance, placed in a sealed container, and thrown in household trash. Environmental release into wastewater must be avoided [Source 1.1].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pharmacort found in:

A-Z Index: